Business and Finance

DARPA awards the funds for new continuous manufacturing technology

The purchases boost its position in temperature-controlled life sciences

Trump administration's plan sounds good but faces severe operational obstacles

Aphena Pharma and Life Science Logistics announce new facilities as preparations for Covid-19 treatment evolve

Sponsors are hoping for $15 billion to address Covid-19 around the globe

The nonprofit generics maker for hospitals plans to enter consumer markets

Generics trade association is confronting a new, post-pandemic era

Deal is boosted by a $275-million investment from Blackstone Group

The land rush for specialty pharma business appears to be slowing among privately held specialty pharmacies

There are now 11 cell/gene therapies targeting Covid-19 in development

Ed Schoonveld’s compilation on pricing strategies gets updated for the 2020s

Company pitches a mfr-payer-provider-patient collaboration for drug pricing

Acquisitions jump BMS and Takeda into Top 10; Amgen and Gilead fall out

Guidance for companies starting out on the commercialization path

Guidance for companies starting out on the commercialization path

The PBMs’ new trend toward controlling the flow of funds for patient support is raising questions

Former J&J executive will be the organization’s third-ever leader

Milken Institute survey finds nearly 300 therapies and vaccines

Carving out CGTs for payment systems involving government intervention may be an answer

Revenue leakage in contracting and sales execution affects 95% of respondents

Acquisition of Cumberland Life Sciences boosts its client base and range of services

Now a Danaher Corp. asset, the former GE Healthcare Life Sciences business has been reshuffled

Newly initiated trials may prove value—but even then, supplies may be limited, and hoarding is already occurring

US list-price sales reached $510 billion in 2019

Copenhagen, Denmark tops Boyd Co.’s list with the highest annual operating costs

But: the growth number of companies is exceeding the growth of trials

The big question is how well will the system respond to spikes in demand, and lack of product

PCMA study disputes its members’ harm to brick-and-mortar businesses